American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Medicenna Therapeutics Corp. (MDNAF)

$0.25 +4.32% OTC: MDNAF · 15-min delayed

Public · OTC: MDNAF

Visit website Follow

MDNAFOTC

About Medicenna Therapeutics Corp.

MEDICENNA THERA CORP

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Company facts

Type: Public · OTC: MDNAF
Industry: Pharmaceuticals
Website: Visit site

Registry IDs

Ticker: MDNAF OTC
SEC CIK: 1807983
SIC: 2834 Pharmaceutical Preparations

Embed this company’s badge

Show Medicenna Therapeutics Corp.’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/medicenna-therapeutics-corp/"><img src="https://americancompanies.com/badge/medicenna-therapeutics-corp.svg" alt="Medicenna Therapeutics Corp. — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it, control the page, and earn the Verified badge.

Claim this profile

Track American companies

Create a free account to follow Medicenna Therapeutics Corp. and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

OTC: MDNAF

$0.25 +4.32%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$0.24 $1.19

52-week range

Open: —
Day range: –
Prev close: —
Volume: —

Medicenna Therapeutics Corp. (MDNAF) Stock Price

Trading 79% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Medicenna Therapeutics Corp..

Write a review

Newsroom

News about Medicenna Therapeutics Corp.

Medicenna Therapeutics Reports Fiscal Year 2024 Financial Results and Operational Highlights GlobeNewswire Inc. · 2024-06-27 Medicenna Announces EMA Approval of its Clinical Trial Application to Expand its Phase 1/2 ABILITY-1 Study to Europe GlobeNewswire Inc. · 2024-06-26 Medicenna Reports Significant Survival Benefit in Patients with Recurrent Glioblastoma Following Treatment with Bizaxofusp When Compared to a Matched External Control Arm at the 2024 ASCO Annual Meeting GlobeNewswire Inc. · 2024-06-03 Medicenna To Present Evidence of Durable Single Agent Activity and Potent Immune Effector Response with MDNA11 in the Dose Escalation Portion of Phase 1/2 ABILITY-1 Study at the 10th Annual Oncology Innovation Forum GlobeNewswire Inc. · 2024-05-31 Medicenna to Present Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming Sachs 10th Annual Oncology Innovation Forum GlobeNewswire Inc. · 2024-05-22 Medicenna Provides Update on its Presentations at the 2024 ASCO Annual Meeting GlobeNewswire Inc. · 2024-05-13

News & sentiment via Polygon.io

FAQ

Medicenna Therapeutics Corp.: frequently asked questions

Is Medicenna Therapeutics Corp. an American company?

Medicenna Therapeutics Corp. is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Is Medicenna Therapeutics Corp. publicly traded?

Yes — Medicenna Therapeutics Corp. is a publicly traded company. Its stock trades under the ticker symbol MDNAF on the OTC.

What does Medicenna Therapeutics Corp. do?

Medicenna Therapeutics Corp. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore